LigaChem Biosciences Inc.
Clinical-stage biopharma developing ADCs, immuno-oncology drugs, and small molecules.
141080 | KO
Overview
Corporate Details
- ISIN(s):
- KR7141080002
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 국제과학10로 10 (주)레고켐 바이오사이언스, 대전광역시
- Website:
- https://ligachembio.com/
Description
LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-28 00:00 |
신탁계약해지결과보고서
|
Korean | 16.5 KB | ||
| 2023-12-28 00:00 |
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 23.1 KB | ||
| 2023-12-26 00:00 |
투자판단관련주요경영사항(LCB84(Trop2-ADC,항체-약물 결합체)대상 기술이전계약 체결)
|
Korean | 9.1 KB | ||
| 2023-12-14 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2023-12-01 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 63.9 KB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 1.6 MB | ||
| 2023-10-04 00:00 |
신탁계약에의한취득상황보고서
|
Korean | 23.0 KB | ||
| 2023-08-31 00:00 |
[기재정정]사업보고서 (2022.12)
|
Korean | 2.1 MB | ||
| 2023-08-18 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 91.8 KB | ||
| 2023-08-11 00:00 |
반기보고서 (2023.06)
|
Korean | 1.5 MB | ||
| 2023-07-28 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인)(LCB01-0371 (delpazolid)의 제2상 임상시험의 국내 임상시험계획 (IND) 승인)
|
Korean | 11.8 KB | ||
| 2023-06-28 00:00 |
주요사항보고서(자기주식취득신탁계약체결결정)
|
Korean | 26.1 KB | ||
| 2023-06-22 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정)(Trop-2 항체-약물 복합체 (ADC) LCB84의 제 1/2상 임상시험의 미국 임상시험계…
|
Korean | 13.5 KB | ||
| 2023-06-20 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인신청)(LCB01-0371 (delpazolid)의 제2상 임상시험의 국내 임상시험계획 (IND) 승…
|
Korean | 11.0 KB | ||
| 2023-05-24 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(Trop-2 항체-약물 복합체 (ADC) LCB84의 제 1/2상 임상시험의 미국 임상시험계획(I…
|
Korean | 9.6 KB |
Automate Your Workflow. Get a real-time feed of all LigaChem Biosciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for LigaChem Biosciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for LigaChem Biosciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
